LCM
COGT icon

Legato Capital Management’s Cogent Biosciences COGT Stock Holding History

Legato Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$623K Sell
16,198
-16,542
-51% -$611K 0.06% 479
2025
Q4 		$1.16M Buy
+32,740
New +$920K 0.1% 317

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Legato Capital Management's COGT Position: Q1 2026 in Review

Legato Capital Management reduced its Cogent Biosciences (COGT) stake by 51% in Q1 2026, selling an estimated $611K and leaving 16,198 shares worth $623K. The position accounts for 0.06% of the portfolio, ranked #479.

Legato Capital Management first reported a position in COGT in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.16M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Legato Capital Management held 16,198 shares of Cogent Biosciences worth $623K as of Q1 2026.
  • Legato Capital Management sold 16,542 Cogent Biosciences shares in Q1 2026, an estimated $611K.
  • Cogent Biosciences made up 0.06% of Legato Capital Management's portfolio in Q1 2026, its #479 holding.
  • Legato Capital Management first reported a position in Cogent Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Legato Capital Management's Cogent Biosciences position peaked at $1.16M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.